An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report
Abstract Background In the current treatment landscape for non-small cell lung cancers, epidermal growth factor receptor-tyrosine kinase inhibitors have emerged as a well-established treatment option for patients with advanced or metastatic disease. This is particularly true for those with commonly...
Main Authors: | Sara Boukansa, Ismail Mouhrach, Fatima El Agy, Laila Bouguenouch, Mounia Serraj, Bouchra Amara, Yassine Ouadnouni, Mohamed Smahi, Badreeddine Alami, Nawfel Mellas, Zineb Benbrahim, Hinde El Fatemi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13256-024-04422-5 |
Similar Items
-
Heterogeneous distribution of EGFR mutation in NSCLC: Case report
by: Sara Boukansa, et al.
Published: (2023-01-01) -
Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report
by: Sara Boukansa, et al.
Published: (2024-01-01) -
Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib
by: Michihiro Kunishige, et al.
Published: (2023-02-01) -
“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
by: Luo FX, et al.
Published: (2024-05-01) -
Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
by: Yueming He, et al.
Published: (2024-11-01)